Lannett Encouraged By Levothyroxine Development In Florida

Lannett Company, Inc. (AMEX: LCI) said it is encouraged by a legal development in Florida that could remove generic Levothyroxine Sodium from the state’s negative drug formulary. An administrative judge in Florida recently found that the inclusion of Levothyroxine on the state’s negative drug formulary is an invalid exercise of legislative authority and that the product should be removed from the negative formulary.

More: continued here

Filed under: Endocrinology on February 13th, 2008